# A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Study · id `cardio:ct-nct05901831` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05901831](<https://clinicaltrials.gov/study/NCT05901831>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05901831

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.

## Technical summary

Registry record NCT05901831. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-26 (actual); primary completion 2025-08-20 (actual). Results posted on 2026-10-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 242 participants (enrolled count; ClinicalTrials.gov record NCT05901831, source copy `cardio:ctgov-nct05901831-2026-10-27`, retrieved 2026-10-31)
- Started: 2024-02-26 (actual) (ClinicalTrials.gov record NCT05901831, source copy `cardio:ctgov-nct05901831-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2025-08-20 (actual) (ClinicalTrials.gov record NCT05901831, source copy `cardio:ctgov-nct05901831-2026-10-27`, retrieved 2026-10-31)
- Completion: 2025-09-15 (actual) (ClinicalTrials.gov record NCT05901831, source copy `cardio:ctgov-nct05901831-2026-10-27`, retrieved 2026-10-31)
- Results first posted: 2026-10-27 (ClinicalTrials.gov record NCT05901831, source copy `cardio:ctgov-nct05901831-2026-10-27`, retrieved 2026-10-31)
- Countries: United States; Canada; China; Denmark; Germany; Italy; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT05901831, source copy `cardio:ctgov-nct05901831-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05901831-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
- Acronym: FINE-ONE
- Condition: Chronic Kidney Disease
- Condition: Type 1 Diabetes Mellitus
- Intervention (Drug): Finerenone
- Intervention (Other): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Type 1 diabetes (`core:type-1-diabetes`)
- Registry intervention name matches this record: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Finerenone in Type 1 Diabetes and Chronic Kidney Disease (`cardio:pubmed-41780000`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d7fd286f4411d74fba1490ec13002569a63a21c98f7a054d67a9db29cda04588
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
